D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 43 Citations 6,968 168 World Ranking 3353 National Ranking 23

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Immune system
  • Antibody

Bjarne Bogen mostly deals with Molecular biology, Antigen, Immunology, T cell and Cytotoxic T cell. His biological study spans a wide range of topics, including Thymocyte, CD8, Idiotype, T-cell receptor and Major histocompatibility complex. His research integrates issues of Immune system and Cell biology in his study of Antigen.

His study on Immunology is mostly dedicated to connecting different topics, such as Receptor. He interconnects Cancer research and B cell in the investigation of issues within Cytotoxic T cell. His Antigen-presenting cell research integrates issues from Natural killer T cell and Antigen presentation.

His most cited work include:

  • Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species. (409 citations)
  • The Inhibitor of Death Receptor Signaling, Flice-Inhibitory Protein Defines a New Class of Tumor Progression Factors (382 citations)
  • Endocytic pathways regulate Toll‐like receptor 4 signaling and link innate and adaptive immunity (366 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Antigen, Immunology, Molecular biology, Immune system and Cytotoxic T cell. His Antigen research includes elements of T cell, Antigen-presenting cell and Antibody. His Antigen-presenting cell research is multidisciplinary, relying on both Antigen processing, MHC class I and Antigen presentation.

Bjarne Bogen has researched Immunology in several fields, including Cancer research and CD40. His research in Molecular biology intersects with topics in CD8, Idiotype, T-cell receptor, Epitope and Major histocompatibility complex. As a part of the same scientific family, Bjarne Bogen mostly works in the field of MHC class II, focusing on Cell biology and, on occasion, Fusion protein and Apoptosis.

He most often published in these fields:

  • Antigen (51.25%)
  • Immunology (43.33%)
  • Molecular biology (36.67%)

What were the highlights of his more recent work (between 2017-2021)?

  • Antigen (51.25%)
  • Cell biology (19.58%)
  • Immune system (31.25%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Antigen, Cell biology, Immune system, MHC class II and Cancer research. His Antigen study combines topics from a wide range of disciplines, such as Cytotoxic T cell, Antibody and Germinal center. The Cell biology study combines topics in areas such as Cross-presentation, Antigen-presenting cell and B cell.

His MHC class II study combines topics in areas such as Cancer cell, Epitope and Immunotherapy. He works mostly in the field of Cancer research, limiting it down to topics relating to Multiple myeloma and, in certain cases, Bone marrow and Bone resorption. His T cell study necessitates a more in-depth grasp of Immunology.

Between 2017 and 2021, his most popular works were:

  • Tumor Killing by CD4+ T Cells Is Mediated via Induction of Inducible Nitric Oxide Synthase-Dependent Macrophage Cytotoxicity. (22 citations)
  • Tumor Killing by CD4+ T Cells Is Mediated via Induction of Inducible Nitric Oxide Synthase-Dependent Macrophage Cytotoxicity. (22 citations)
  • CD4+ T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs (22 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Immune system
  • Antibody

His primary areas of study are Antigen, Cell biology, MHC class II, Immune system and T cell. His Antigen study frequently links to adjacent areas such as Cancer research. His Cell biology research includes themes of Cancer cell, T-cell receptor and Immunotherapy.

His MHC class II research incorporates themes from Epitope, Priming, Tumor antigen and Antigen presentation. His study on Immune system is covered under Immunology. T cell is closely attributed to Antibody in his research.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Endocytic pathways regulate Toll‐like receptor 4 signaling and link innate and adaptive immunity

Harald Husebye;Øyvind Halaas;Harald Stenmark;Harald Stenmark;Gro Tunheim.
The EMBO Journal (2006)

506 Citations

The Inhibitor of Death Receptor Signaling, Flice-Inhibitory Protein Defines a New Class of Tumor Progression Factors

Mounira Djerbi;Valentina Screpanti;Anca Irinel Catrina;Bjarne Bogen.
Journal of Experimental Medicine (1999)

498 Citations

Primary antitumor immune response mediated by CD4+ T cells.

Alexandre Corthay;Dag K. Skovseth;Katrin U. Lundin;Egil Røsjø.
Immunity (2005)

438 Citations

Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species.

Martin Guilliams;Martin Guilliams;Charles-Antoine Dutertre;Charles-Antoine Dutertre;Charlotte L. Scott;Naomi McGovern.
Immunity (2016)

395 Citations

MHC class II-restricted presentation of intracellular antigen.

Siegfried Weiss;Bjarne Bogen.
Cell (1991)

346 Citations

B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells.

Siegfried Weiss;Bjarne Bogen.
Proceedings of the National Academy of Sciences of the United States of America (1989)

312 Citations

Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer

Ole Audun Werner Haabeth;Kristina Berg Lorvik;Clara Hammarström;Ian M. Donaldson.
Nature Communications (2011)

246 Citations

Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma.

Bjarne Bogen.
European Journal of Immunology (1996)

225 Citations

Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8α+ type.

Karine Crozat;Samira Tamoutounour;Thien-Phong Vu Manh;Even Fossum.
Journal of Immunology (2011)

173 Citations

How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

Ole Audun Haabeth;Anders Tveita;Marte Hotvedt Fauskanger;Fredrik Hellem Schjesvold.
Frontiers in Immunology (2014)

172 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Bjarne Bogen

Florent Ginhoux

Florent Ginhoux

Agency for Science, Technology and Research

Publications: 54

Marc Dalod

Marc Dalod

Centre d’Immunologie de Marseille-Luminy

Publications: 46

Bart N. Lambrecht

Bart N. Lambrecht

Ghent University

Publications: 36

Jacques Banchereau

Jacques Banchereau

Immunai

Publications: 22

Larry W. Kwak

Larry W. Kwak

City Of Hope National Medical Center

Publications: 21

Freda K. Stevenson

Freda K. Stevenson

University of Southampton

Publications: 20

Andrew J. Murphy

Andrew J. Murphy

Regeneron (United States)

Publications: 17

Terje Espevik

Terje Espevik

Norwegian University of Science and Technology

Publications: 17

Hamida Hammad

Hamida Hammad

Ghent University

Publications: 17

Bernard Malissen

Bernard Malissen

Aix-Marseille University

Publications: 16

William W. Agace

William W. Agace

Technical University of Denmark

Publications: 16

Irina Caminschi

Irina Caminschi

Monash University

Publications: 16

Inger Sandlie

Inger Sandlie

University of Oslo

Publications: 16

Ronald Levy

Ronald Levy

Stanford University

Publications: 15

Martin Guilliams

Martin Guilliams

Ghent University

Publications: 15

Madhav V. Dhodapkar

Madhav V. Dhodapkar

Emory University

Publications: 14

Something went wrong. Please try again later.